<DOC>
	<DOCNO>NCT00238875</DOCNO>
	<brief_summary>To evaluate efficacy safety SBRT T1N0M0 non-small cell lung cancer</brief_summary>
	<brief_title>A Phase II Study Stereotactic Body Radiation Therapy Patients With T1N0M0 Non-small Cell Lung Cancer ( JCOG0403 )</brief_title>
	<detailed_description>To evaluate efficacy safety SBRT T1N0M0 non-small cell lung cancer，the follow question answer . Can SRT alternative standard treatment modality inoperable patient ? Can SRT comparable standard treatment modality lobectomy operable patient ? 12 Gy daily dose isocenter，and 48 Gy total 4 fraction irradiate stereotactic irradiation 4 8 day .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histologically transbronchoscopic cytologically confirm nonsmall cell lung cancer 2 . Stage IA image within 28 day 3 . No intrathoracic lesion 4 . Dose constraint organ risk seem limit within range 5 . Operable ( Standard Limited surgery ) Inoperable 6 . Age &gt; =20 7 . No previous thoracic radiation 8 . No previous chemotherapy 9 . ECOG PS=02 10 . Respiratory function ( &lt; =14 day ) PaO2 &gt; =60 torr FEV1.0 &gt; =700 ml 11 . Written inform consent 1 . No apparent radiation pneumonitis fibrosis 2 . No active tuberculosis without oral drug 3 . No double cancer 4 . No pregnancy 5 . No psychiatric disorder 6 . No steroid administration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stereotactic body radiation therapy</keyword>
	<keyword>T1N0M0 non-small cell lung cancer</keyword>
	<keyword>radiotherapy</keyword>
</DOC>